Abstract:Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare and progressive disease caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP). This results in a systemic accumulation of nucleosides and mitochondrial toxicity. AAV-based liver-directed gene therapy has shown efficacy in preclinical studies, but it has limitations such as a decline of transgene expression long-term. We propose that gene editing can circumvent some of these problems.Methods: We performed a preclinical study in the murine model of MNGIE to assess that the coordinated delivery of CRISPR/Cas9 and a TYMP cDNA caused the efficient integration of a TYMP transgene into introns of the Tymp and Alb loci in hepatocytes. CRISPR/Cas9 was delivered either as mRNA using nanoparticles or in AAV2/8 viral vectors; the latter were also used to package the TYMP cDNA. We assessed the efficient integration of the templates into the liver cells, and monitored the nucleoside levels in plasma to detect the biochemical correction.Findings: The best results were obtained using lipid nanoparticles. The consistent and stable nucleoside reduction observed correlated with the presence of TYMP mRNA and functional enzyme in the liver cells. In mice with an edited Alb locus, the transgene produced a hybrid Alb-hTP protein that was secreted, with high levels of TP activity in plasma.Interpretation: Liver-directed gene editing is a feasible approach to achieve the long-term biochemical correction of the disease, with several advantages over previous methods.Funding Information: This project was made possible with financial support from the Instituto de Salud Carlos III/FEDER (grant PI15/00172) and from MINECO/FEDER (grant RTI2018-094734-B-C22). The support of the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya, through SGR 2017 1559 grant, is also acknowledged.Declaration of Interests: S.H.Y.F. and Y.K.T. are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticle delivery systems for nucleic-acid-based drugs. RM was the recipient of personal fees associated with advisory tasks and of financial support from Modis Therapeutics for research outside the submitted work. RM also holds a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110), with royalties paid to Modis Therapeutics.INCOMPLETEEthics Approval Statement: All animal procedures were performed in accordance with European recommendations and were approved by our institutional ethics committee (Comitè Ètic d’Experimentació Animal).

Treatment of a genetic liver disease in mice through transient prime editor expression

In vivo prime editing of a metabolic liver disease in mice

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Efficient prime editing in mouse brain, liver and heart with dual AAVs

Improved Prime Editors Enable Pathogenic Allele Correction and Cancer Modelling in Adult Mice

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing

Improved specificity and efficacy of base-editing therapies with hybrid guide RNAs

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver

Prime Editing for Human Gene Therapy: Where Are We Now?

Prime Editing: Current Advances and Therapeutic Opportunities in Human Diseases.

Therapeutic liver cell transplantation to treat murine PKU

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Amelioration of Metabolic and Behavioral Defects Through Base Editing in the PahR408W Phenylketonuria Mouse Model

Prime editing for functional repair in patient-derived disease models

A selectable all-in-one CRISPR prime editing piggyBac transposon allows for highly efficient gene editing in human cell lines

Evolution of Prime Editing Systems: Move Forward to the Treatment of Hereditary Diseases

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE